Cargando…

Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection

INTRODUCTION: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes. PURPOSE: To co...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Jillian Kallman, Gerber, Lynn H, Stepanova, Maria, de Avila, Leyla, Weinstein, Ali A, Pham, Huong, Nader, Fatema, Afendy, Mariam, Terra, Kathy, Austin, Patrick, Keo, Wisna’odom, Racila, Andrei, Estep, James Michael, Gerber, Suzannah, Verma, Manisha, Golabi, Pegah, Lam, Brian P, Younossi, Zobair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145429/
https://www.ncbi.nlm.nih.gov/pubmed/37123886
http://dx.doi.org/10.2147/IJGM.S406571
_version_ 1785034331306065920
author Price, Jillian Kallman
Gerber, Lynn H
Stepanova, Maria
de Avila, Leyla
Weinstein, Ali A
Pham, Huong
Nader, Fatema
Afendy, Mariam
Terra, Kathy
Austin, Patrick
Keo, Wisna’odom
Racila, Andrei
Estep, James Michael
Gerber, Suzannah
Verma, Manisha
Golabi, Pegah
Lam, Brian P
Younossi, Zobair
author_facet Price, Jillian Kallman
Gerber, Lynn H
Stepanova, Maria
de Avila, Leyla
Weinstein, Ali A
Pham, Huong
Nader, Fatema
Afendy, Mariam
Terra, Kathy
Austin, Patrick
Keo, Wisna’odom
Racila, Andrei
Estep, James Michael
Gerber, Suzannah
Verma, Manisha
Golabi, Pegah
Lam, Brian P
Younossi, Zobair
author_sort Price, Jillian Kallman
collection PubMed
description INTRODUCTION: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes. PURPOSE: To compare patient perception of PASC symptoms for those receiving bamlanivimab or casirivimab and imdevimab (mAbs) to those not receiving this treatment (non-mAbs). To compare changes between these groups in symptoms, function and quality of life over a 6-month follow-up. PATIENTS AND METHODS: Consented adults >28 days post-infection with positive SARS-CoV-2 qPCR or antigen test and SARS-CoV-2 infection between March of 2020 and July of 2022 were enrolled. This prospective, repeated measure observational study reports baseline through 6-month follow-up. Extensive sociodemographic data, detailed medical history, COVID-19 symptom history, and standardized measures of well-being, depression, anxiety, stigma, cognition, symptom assessment, distress, and health status were collected. RESULTS: 323 participants [101 mAb, 221 non-mAb, 52.7±15.5 years, 47.7% male, body mass index (BMI) 31.4±8.4] were analyzed. Fewer symptoms at baseline were reported in mAb versus non-mAb participants (1.06±1.31 vs 1.78±2.15, respectively p=0.0177) 6 months: (0.911±1.276 mAb vs.1.75±2.22 non-mAb, p=0.0427). Both groups showed significant within-group decreases in symptom number (52 to 21 mAb, 126 to 63 non-mAb) and symptom burden (p=0.0088 mAb, p<0.00001 non-mAb). mAb patients had significantly shorter infection-to-baseline interval (days) (120.4±55.3 mAb vs 194.0±89.3 non-mAb, p<0.00001); less frequent history of myocardial infarction (0.0 vs 3.9%, p=0.0464); headache (2.0% vs.11.8%, p=0.0046), rash (3.1% vs 9.9%, p=0.0377), and miscellaneous muscle complaints (2.0% vs 12.3%, p=0.0035), plus significantly better 6-month mood. (2.2% vs 13.2%, p=0.0390). CONCLUSION: mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up.
format Online
Article
Text
id pubmed-10145429
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101454292023-04-29 Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection Price, Jillian Kallman Gerber, Lynn H Stepanova, Maria de Avila, Leyla Weinstein, Ali A Pham, Huong Nader, Fatema Afendy, Mariam Terra, Kathy Austin, Patrick Keo, Wisna’odom Racila, Andrei Estep, James Michael Gerber, Suzannah Verma, Manisha Golabi, Pegah Lam, Brian P Younossi, Zobair Int J Gen Med Original Research INTRODUCTION: Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes. PURPOSE: To compare patient perception of PASC symptoms for those receiving bamlanivimab or casirivimab and imdevimab (mAbs) to those not receiving this treatment (non-mAbs). To compare changes between these groups in symptoms, function and quality of life over a 6-month follow-up. PATIENTS AND METHODS: Consented adults >28 days post-infection with positive SARS-CoV-2 qPCR or antigen test and SARS-CoV-2 infection between March of 2020 and July of 2022 were enrolled. This prospective, repeated measure observational study reports baseline through 6-month follow-up. Extensive sociodemographic data, detailed medical history, COVID-19 symptom history, and standardized measures of well-being, depression, anxiety, stigma, cognition, symptom assessment, distress, and health status were collected. RESULTS: 323 participants [101 mAb, 221 non-mAb, 52.7±15.5 years, 47.7% male, body mass index (BMI) 31.4±8.4] were analyzed. Fewer symptoms at baseline were reported in mAb versus non-mAb participants (1.06±1.31 vs 1.78±2.15, respectively p=0.0177) 6 months: (0.911±1.276 mAb vs.1.75±2.22 non-mAb, p=0.0427). Both groups showed significant within-group decreases in symptom number (52 to 21 mAb, 126 to 63 non-mAb) and symptom burden (p=0.0088 mAb, p<0.00001 non-mAb). mAb patients had significantly shorter infection-to-baseline interval (days) (120.4±55.3 mAb vs 194.0±89.3 non-mAb, p<0.00001); less frequent history of myocardial infarction (0.0 vs 3.9%, p=0.0464); headache (2.0% vs.11.8%, p=0.0046), rash (3.1% vs 9.9%, p=0.0377), and miscellaneous muscle complaints (2.0% vs 12.3%, p=0.0035), plus significantly better 6-month mood. (2.2% vs 13.2%, p=0.0390). CONCLUSION: mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up. Dove 2023-04-24 /pmc/articles/PMC10145429/ /pubmed/37123886 http://dx.doi.org/10.2147/IJGM.S406571 Text en © 2023 Price et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Price, Jillian Kallman
Gerber, Lynn H
Stepanova, Maria
de Avila, Leyla
Weinstein, Ali A
Pham, Huong
Nader, Fatema
Afendy, Mariam
Terra, Kathy
Austin, Patrick
Keo, Wisna’odom
Racila, Andrei
Estep, James Michael
Gerber, Suzannah
Verma, Manisha
Golabi, Pegah
Lam, Brian P
Younossi, Zobair
Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
title Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
title_full Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
title_fullStr Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
title_full_unstemmed Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
title_short Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
title_sort post-acute sars-cov-2 symptoms are fewer, less intense over time in people treated with mono-clonal antibodies for acute infection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145429/
https://www.ncbi.nlm.nih.gov/pubmed/37123886
http://dx.doi.org/10.2147/IJGM.S406571
work_keys_str_mv AT pricejilliankallman postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT gerberlynnh postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT stepanovamaria postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT deavilaleyla postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT weinsteinalia postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT phamhuong postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT naderfatema postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT afendymariam postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT terrakathy postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT austinpatrick postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT keowisnaodom postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT racilaandrei postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT estepjamesmichael postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT gerbersuzannah postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT vermamanisha postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT golabipegah postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT lambrianp postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection
AT younossizobair postacutesarscov2symptomsarefewerlessintenseovertimeinpeopletreatedwithmonoclonalantibodiesforacuteinfection